Tarsier Pharma's planned July 2026 IPO on NYSE American, targeting roughly $294–299 million fully diluted market cap via a $45–50 million raise at $8–10 per share, failed to close amid the passage of key filing deadlines and the absence of subsequent updates as of mid-August. This outcome aligns with subdued biotech IPO activity, the company's pre-revenue Phase 3 status focused on ocular inflammatory therapies, and typical delays for smaller issuers navigating regulatory and market conditions. Trader consensus at 98.6% for no IPO before September 2026 reflects these execution risks, though fresh F-1 amendments, initiation of the Tarsier-04 trial in Q3 2026, or broader equity market improvement could reopen a path to pricing within the $250–450 million ranges.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoNessuna IPO prima di settembre 2026 98.6%
$400M-$450M 2.6%
$250M-$300M 1.8%
350-400 milioni di dollari 1.6%
$15,117 Vol.
$15,117 Vol.
9 lug 2026
<250 milioni di dollari
<1%
$250M-$300M
2%
$300M-$350M
<1%
350-400 milioni di dollari
2%
$400M-$450M
3%
>450 milioni di dollari
<1%
Nessuna IPO prima di settembre 2026
99%
Nessuna IPO prima di settembre 2026 98.6%
$400M-$450M 2.6%
$250M-$300M 1.8%
350-400 milioni di dollari 1.6%
$15,117 Vol.
$15,117 Vol.
9 lug 2026
<250 milioni di dollari
$907 Vol.
<1%
$250M-$300M
$979 Vol.
2%
$300M-$350M
$561 Vol.
<1%
350-400 milioni di dollari
$561 Vol.
2%
$400M-$450M
$349 Vol.
3%
>450 milioni di dollari
$680 Vol.
<1%
Nessuna IPO prima di settembre 2026
$11,080 Vol.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned July 2026 IPO on NYSE American, targeting roughly $294–299 million fully diluted market cap via a $45–50 million raise at $8–10 per share, failed to close amid the passage of key filing deadlines and the absence of subsequent updates as of mid-August. This outcome aligns with subdued biotech IPO activity, the company's pre-revenue Phase 3 status focused on ocular inflammatory therapies, and typical delays for smaller issuers navigating regulatory and market conditions. Trader consensus at 98.6% for no IPO before September 2026 reflects these execution risks, though fresh F-1 amendments, initiation of the Tarsier-04 trial in Q3 2026, or broader equity market improvement could reopen a path to pricing within the $250–450 million ranges.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Mercato aperto: Jul 7, 2026, 9:12 AM ET
Volume
$15,117Data di fine
9 lug 2026Mercato aperto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's planned July 2026 IPO on NYSE American, targeting roughly $294–299 million fully diluted market cap via a $45–50 million raise at $8–10 per share, failed to close amid the passage of key filing deadlines and the absence of subsequent updates as of mid-August. This outcome aligns with subdued biotech IPO activity, the company's pre-revenue Phase 3 status focused on ocular inflammatory therapies, and typical delays for smaller issuers navigating regulatory and market conditions. Trader consensus at 98.6% for no IPO before September 2026 reflects these execution risks, though fresh F-1 amendments, initiation of the Tarsier-04 trial in Q3 2026, or broader equity market improvement could reopen a path to pricing within the $250–450 million ranges.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$15,117Data di fine
9 lug 2026Mercato aperto
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's planned July 2026 IPO on NYSE American, targeting roughly $294–299 million fully diluted market cap via a $45–50 million raise at $8–10 per share, failed to close amid the passage of key filing deadlines and the absence of subsequent updates as of mid-August. This outcome aligns with subdued biotech IPO activity, the company's pre-revenue Phase 3 status focused on ocular inflammatory therapies, and typical delays for smaller issuers navigating regulatory and market conditions. Trader consensus at 98.6% for no IPO before September 2026 reflects these execution risks, though fresh F-1 amendments, initiation of the Tarsier-04 trial in Q3 2026, or broader equity market improvement could reopen a path to pricing within the $250–450 million ranges.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti